Mr. Kuntal Pancholi served as CFO until May 28, 2026
Mr. Nitesh Bohra appointed as CFO from May 29, 2026
CS Priyanka Gupta resigned as Company Secretary effective September 30, 2025
CS Padma Tapariya appointed as Company Secretary from October 01, 2025
AGM Details
37th Annual General Meeting to be held on August 11, 2026 at 11:30 AM IST through Video Conferencing/Other Audio-Visual Means
Ordinary business includes adoption of financial statements and reappointment of Mr. Kiran Kulkarni who retires by rotation
Special business includes ratification of Cost Auditor remuneration (₹60,000 plus taxes) and reappointment of Mr. Kiran Kulkarni as Whole-Time Director for 3 years from May 24, 2027
Auditor Appointments
Statutory Auditors: B.L. Dasharda & Associates (appointed for 5 years from 36th AGM)
Cost Auditors: Poddar & Co. (remuneration ₹60,000 plus taxes for FY 2026-27)
Secretarial Auditors: GMJ & Associates (appointed for 5 years from April 01, 2025 to March 31, 2030)
Corporate Governance
Board consists of 6 members (3 Executive, 3 Independent including one woman director)
Seven Board meetings held during the year
All committees (Audit, Nomination & Remuneration, Stakeholders Relationship) constituted and functional
Other Significant Information
No dividend declared for FY 2025-26
No material related party transactions
No deposits accepted from public
No subsidiaries, joint ventures or associate companies
Plant located at K-56, MIDC Tarapur, Dist. Palghar, Maharashtra
88.96% of shares held in dematerialized form
Promoter holding: 52.18%
Forward-looking Statements
Company completed capacity expansion of Metformin HCL from 1800 MTA to 3600 MTA
Benefit of capacity expansion expected to reflect in future quarters
Focus on operating with highest EHS standards while improving efficiencies
